(Total Views: 247)
Posted On: 09/08/2017 4:40:14 PM
Post# of 72447
Strategic Direction
- Leverage 2017 Milestones to Support Partnering Opportunities
• Multiple CDAs Signed, Ongoing Interactions with Big Pharma and other Global Rx Companies
- Advance Formulation Work to Tailor Drug Delivery
- Continue to Build Value by Addressing Areas of Unmet Medical Need for
the Benefit of Patients and Shareholders
- Anchor Each Drug Candidate in Additional Trials to Further Provide
Favorable Return-On-Investment
- Leverage 2017 Milestones to Support Partnering Opportunities
• Multiple CDAs Signed, Ongoing Interactions with Big Pharma and other Global Rx Companies
- Advance Formulation Work to Tailor Drug Delivery
- Continue to Build Value by Addressing Areas of Unmet Medical Need for
the Benefit of Patients and Shareholders
- Anchor Each Drug Candidate in Additional Trials to Further Provide
Favorable Return-On-Investment
(0)
(0)
